Beta

    when fda approve intellia therapeutics' lonvo-z

    Before October 2027

    when fda approve intellia therapeutics' lonvo-z. Best Yes near 50¢ across 1 platform. Live cross-platform prices. Not financial advice.

    Best Yes: 50¢ · Best No: 60¢ · 1 platform

    • Kalshi: Yes 50¢ / No 60¢
    LIVE

    Before October 2027

    Volume

    $280

    $0 24h

    Platforms

    1

    Cross-platform pricing

    Resolution

    Resolves Oct 1, 2027

    ~472 days left

    Category

    Culture

    50¢CHANCE OF YES45%55%
    Yes
    50¢
    Kalshi
    No
    60¢
    Kalshi

    Opens on best-price platform

    Compare & Trade

    1 platform
    KalshiKalshi
    Best Yes
    Best No
    Yes
    50¢
    No
    60¢
    Vol
    $280
    Trade on Kalshi

    Price History

    Loading…

    About This Market

    If the FDA approves Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema for marketing before Oct 1, 2027, then the market resolves to Yes.

    Fee Impact at These Prices

    KalshiKalshiat 50¢: exit costs ~1.75¢/contract
    Full calculator

    Market Details

    ResolutionResolves Oct 1, 2027
    Time Left472 days
    Status● Active
    CategoryCulture

    Sign in to join the discussion

    Sign In